Description

Mirapex PD Tablets with Prolonged Release 0.75 mg. №30

Ingredients

Each tablet contains 0.75 mg of pramipexole dihydrochloride monohydrate as the active ingredient.

Dosage

The recommended dosage is determined by your healthcare provider and is based on your medical condition and response to treatment.

Indications

Mirapex PD tablets are indicated for the treatment of Parkinson’s disease. It helps improve muscle control and reduce stiffness, allowing for better movement.

Contraindications

Do not use Mirapex PD tablets if you are allergic to pramipexole or any other ingredients in the formulation. It is important to inform your doctor about any medical conditions you have before starting this medication.

Directions

Take Mirapex PD tablets exactly as prescribed by your healthcare provider. The tablets should be swallowed whole with a glass of water. Do not crush or chew the tablets.

Scientific Evidence

Studies have shown that pramipexole, the active ingredient in Mirapex PD tablets, effectively improves motor symptoms in patients with Parkinson’s disease. Research published in the Journal of Neurology indicates that pramipexole has a positive impact on both early and advanced stages of the disease.

Additional Information

It is important to follow your doctor’s instructions carefully while taking Mirapex PD tablets. Regular follow-up appointments are necessary to monitor your progress and adjust the dosage if needed.

Mirapex PD tablets with prolonged release 0.75 mg. №30 provide a convenient once-daily dosing option for individuals with Parkinson’s disease. The prolonged-release formulation ensures a steady level of medication in the body, reducing fluctuations in symptom control throughout the day.

Pharmacologically, pramipexole acts as a dopamine agonist, stimulating dopamine receptors in the brain. By mimicking the action of dopamine, pramipexole helps to improve motor function and reduce symptoms of Parkinson’s disease. Compared to other dopamine agonists, pramipexole has shown favorable efficacy and tolerability profiles in clinical trials.